CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia, Relapsed, Adult Clinical Trial

Official title:
Chidamide, Decitabine Combined With Priming IAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Status Completed

Clinical Trial Summary

This study is to investigate the therapeutic efficacy and side effect of chidamide, decitabine combined with priming IAG regimen for relapsed or refractroy acute myeloid leukemia

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Acute Myeloid Leukemia, Relapsed, Adult
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute

Clinical Trial Details

NCT number	NCT03985007
Study type	Interventional
Source	The First Affiliated Hospital of Soochow University
Contact
Status	Completed
Phase	Phase 2
Start date	January 1, 2018
Completion date	March 16, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04050280` - CLAG-GO for Patients With Persistent, Relapsed or Refractory AML	Phase 2
Terminated	`NCT03063203` - Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia	Phase 2
Recruiting	`NCT04347616` - Natural Killer-cell Therapy for Acute Myeloid Leukemia	Phase 1/Phase 2
Terminated	`NCT02957032` - A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation	Phase 1